Menu Search
Equities

Inhibikase Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IQT0:MUN

Inhibikase Therapeutics Inc

Actions
  • Price (EUR)2.50
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.8291
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.66m
  • Incorporated2010
  • Employees15.00
  • Location
    Inhibikase Therapeutics Inc1000 N. West Street, Suite 1200WILMINGTON 19801United StatesUSA
  • Phone+1 (302) 295-3800
  • Fax+1 (302) 655-5049
  • Websitehttps://www.inhibikase.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IKT:NAQ since
announced		Transaction
value
CorHepta Pharmaceuticals IncDeal completed21 Feb 202521 Feb 2025Deal completed-47.55%16.23m
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.